HK1257220A1 - 使用包含脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法 - Google Patents
使用包含脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法Info
- Publication number
- HK1257220A1 HK1257220A1 HK18116225.3A HK18116225A HK1257220A1 HK 1257220 A1 HK1257220 A1 HK 1257220A1 HK 18116225 A HK18116225 A HK 18116225A HK 1257220 A1 HK1257220 A1 HK 1257220A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- oxaliplatin
- methods
- pancreatic cancer
- combination therapies
- metastatic pancreatic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562208209P | 2015-08-21 | 2015-08-21 | |
US201562216736P | 2015-09-10 | 2015-09-10 | |
US201562273244P | 2015-12-30 | 2015-12-30 | |
US201662281473P | 2016-01-21 | 2016-01-21 | |
US201662302341P | 2016-03-02 | 2016-03-02 | |
US201662323245P | 2016-04-15 | 2016-04-15 | |
US201662343313P | 2016-05-31 | 2016-05-31 | |
PCT/US2016/047727 WO2017034957A1 (en) | 2015-08-21 | 2016-08-19 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257220A1 true HK1257220A1 (zh) | 2019-10-18 |
Family
ID=58100730
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116225.3A HK1257220A1 (zh) | 2015-08-21 | 2018-12-18 | 使用包含脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法 |
HK18116310.9A HK1257250A1 (zh) | 2015-08-21 | 2018-12-19 | 使用包括脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116310.9A HK1257250A1 (zh) | 2015-08-21 | 2018-12-19 | 使用包括脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法 |
Country Status (18)
Country | Link |
---|---|
US (3) | US20170049775A1 (zh) |
EP (2) | EP3791876A1 (zh) |
JP (3) | JP2018528185A (zh) |
KR (1) | KR20180039087A (zh) |
CN (1) | CN108495629A (zh) |
AU (1) | AU2016310476B8 (zh) |
BR (1) | BR112018002941B1 (zh) |
CA (1) | CA2993451A1 (zh) |
ES (1) | ES2826826T3 (zh) |
HK (2) | HK1257220A1 (zh) |
IL (1) | IL257149A (zh) |
MX (1) | MX2018001802A (zh) |
PT (1) | PT3337478T (zh) |
RU (1) | RU2747124C2 (zh) |
SG (1) | SG10201913077QA (zh) |
SI (1) | SI3337478T1 (zh) |
TW (4) | TW202126293A (zh) |
WO (1) | WO2017034957A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
AU2015360761B2 (en) * | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
PT3337467T (pt) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Terapia de combinação utilizando irinotecano lipossomal e um inibidor parp para tratamento do cancro |
WO2017034957A1 (en) | 2015-08-21 | 2017-03-02 | Merrimack Pharmaceuticals, Inc. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
AU2016340153B2 (en) | 2015-10-16 | 2022-06-02 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
WO2018083470A1 (en) * | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
WO2020079692A1 (en) * | 2018-10-17 | 2020-04-23 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
US20220072087A1 (en) * | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
KR20210130765A (ko) * | 2019-02-22 | 2021-11-01 | 노보큐어 게엠베하 | Xelox, folfox 또는 이들의 각 구성 요소와 ttfield를 조합한 위암 치료 |
US20220378936A1 (en) * | 2019-10-10 | 2022-12-01 | The University Of North Carolina At Chapel Hill | Delivery system complexes comprising a precipitate of an active agent and methods of use |
WO2022266354A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napoli |
WO2022266357A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napox |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
WO1998017256A1 (en) | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
EP1121102B1 (en) | 1998-09-16 | 2003-04-23 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
DE60123583T2 (de) | 2000-02-04 | 2007-08-09 | Lipoxen Technologies Ltd. | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
DK1286671T3 (da) | 2000-05-15 | 2006-07-17 | Celgene Corp | Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan |
DE60115044T2 (de) | 2000-06-30 | 2006-08-03 | Inex Pharmaceuticals Corp., Burnaby | Liposomale antineoplastische arzneimittel und deren verwendungen |
TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
MXPA03008864A (es) | 2001-03-26 | 2004-12-06 | Johnson & Johnson | Composicion de liposoma para el suministro intracelular mejorado en un agente terapeutico. |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
AU2002328945A1 (en) | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
WO2003097805A2 (en) | 2002-05-15 | 2003-11-27 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
EP2431385A3 (en) | 2002-05-31 | 2012-07-04 | Morphotek, Inc. | Combination therapy with chlorotoxin |
WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
KR20170073698A (ko) | 2003-05-30 | 2017-06-28 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
DK1746976T3 (en) | 2004-05-03 | 2017-04-10 | Merrimack Pharmaceuticals Inc | LIPOSOMES SUITABLE FOR PHARMACEUTICAL SUPPLY |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
MXPA06013874A (es) | 2004-06-01 | 2007-04-25 | Terumo Corp | Formulacion de irinotecan. |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
US20100189771A1 (en) | 2005-10-25 | 2010-07-29 | Lawrence Mayer | Fixed ratio drug combination treatments for solid tumors |
WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
CN101370497B (zh) | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | 包含parp抑制剂和细胞毒性剂的联合产品及用途 |
US20070219268A1 (en) | 2006-03-16 | 2007-09-20 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
PT2716301T (pt) | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
WO2009097011A1 (en) | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
WO2009040426A1 (en) | 2007-09-28 | 2009-04-02 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
WO2009064444A2 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
CN101888777A (zh) | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
JP2011515478A (ja) | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | 結腸直腸がんを処置または予防するための方法 |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
KR20110008086A (ko) | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
NZ596365A (en) * | 2009-05-01 | 2013-11-29 | Oncozyme Pharma Inc | Pentamidine combinations for treating cancer |
KR20120089754A (ko) | 2009-12-03 | 2012-08-13 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 이리노테칸 또는 그의 하이드로클로라이드의 리포좀 및 그의 제조 방법 |
RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
WO2012012454A1 (en) | 2010-07-19 | 2012-01-26 | Bipar Sciences, Inc. | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
RU2598711C2 (ru) | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
RU2541100C2 (ru) * | 2010-09-03 | 2015-02-10 | Боард Оф Регентс Оф Зе Юниверсити Оф Небраска | Способ и композиция для лечения рака |
CN107252417A (zh) | 2010-12-06 | 2017-10-17 | 梅里麦克制药股份有限公司 | 在使用包含蒽环类化疗剂的erbb2靶向免疫脂质体的治疗中防止心肌毒性的剂量和给药 |
JP5947807B2 (ja) | 2010-12-14 | 2016-07-06 | テクニカル ユニバーシティ オブ デンマークTechnical University Of Denmark | ナノ粒子組成物への放射性核種の封入 |
WO2012112730A2 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
BR112013027021A2 (pt) | 2011-04-19 | 2016-11-29 | Merrimack Pharmaceuticals Inc | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
AU2013249307B2 (en) | 2012-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
AU2013374248A1 (en) | 2012-12-14 | 2015-06-11 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
RU2668125C2 (ru) | 2013-03-27 | 2018-09-26 | Тайхо Фармасьютикал Ко., Лтд. | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат |
JP2016529284A (ja) | 2013-08-27 | 2016-09-23 | ノースイースタン ユニバーシティ | ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 |
WO2015061592A1 (en) | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
AU2015360761B2 (en) | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
WO2016168451A1 (en) | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
PT3337467T (pt) | 2015-08-20 | 2021-01-25 | Ipsen Biopharm Ltd | Terapia de combinação utilizando irinotecano lipossomal e um inibidor parp para tratamento do cancro |
WO2017034957A1 (en) | 2015-08-21 | 2017-03-02 | Merrimack Pharmaceuticals, Inc. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
AU2016340153B2 (en) | 2015-10-16 | 2022-06-02 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
JP2019516693A (ja) | 2016-05-18 | 2019-06-20 | イプセン バイオファーム リミティド | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
CN106420789A (zh) * | 2016-10-08 | 2017-02-22 | 中国人民解放军总医院 | 复发耐药消化道肿瘤地西他滨综合治疗方案 |
WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
-
2016
- 2016-08-19 WO PCT/US2016/047727 patent/WO2017034957A1/en active Application Filing
- 2016-08-19 CN CN201680046873.3A patent/CN108495629A/zh active Pending
- 2016-08-19 CA CA2993451A patent/CA2993451A1/en active Pending
- 2016-08-19 TW TW109134982A patent/TW202126293A/zh unknown
- 2016-08-19 JP JP2018506600A patent/JP2018528185A/ja not_active Withdrawn
- 2016-08-19 EP EP20190127.9A patent/EP3791876A1/en active Pending
- 2016-08-19 ES ES16758337T patent/ES2826826T3/es active Active
- 2016-08-19 SI SI201630927T patent/SI3337478T1/sl unknown
- 2016-08-19 AU AU2016310476A patent/AU2016310476B8/en active Active
- 2016-08-19 PT PT167583376T patent/PT3337478T/pt unknown
- 2016-08-19 KR KR1020187005220A patent/KR20180039087A/ko not_active Application Discontinuation
- 2016-08-19 SG SG10201913077QA patent/SG10201913077QA/en unknown
- 2016-08-19 US US15/241,106 patent/US20170049775A1/en not_active Abandoned
- 2016-08-19 BR BR112018002941-6A patent/BR112018002941B1/pt active IP Right Grant
- 2016-08-19 TW TW112110238A patent/TW202400181A/zh unknown
- 2016-08-19 MX MX2018001802A patent/MX2018001802A/es unknown
- 2016-08-19 EP EP16758337.6A patent/EP3337478B1/en active Active
- 2016-08-19 TW TW111103869A patent/TW202243677A/zh unknown
- 2016-08-19 TW TW105126833A patent/TWI778942B/zh active
- 2016-08-19 RU RU2018105666A patent/RU2747124C2/ru active
-
2017
- 2017-11-10 US US15/809,815 patent/US11344552B2/en active Active
-
2018
- 2018-01-25 IL IL257149A patent/IL257149A/en unknown
- 2018-12-18 HK HK18116225.3A patent/HK1257220A1/zh unknown
- 2018-12-19 HK HK18116310.9A patent/HK1257250A1/zh unknown
-
2021
- 2021-10-28 JP JP2021176412A patent/JP7463329B2/ja active Active
-
2022
- 2022-04-01 US US17/711,500 patent/US20230062425A1/en active Pending
-
2024
- 2024-02-16 JP JP2024022222A patent/JP2024045587A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257250A1 (zh) | 使用包括脂質體伊立替康和奧沙利鉑的組合療法治療轉移性胰腺癌的方法 | |
ZA201701491B (en) | Methods and therapeutic combinations for treating tumors | |
IL255780A (en) | Therapeutic combinations and methods for treating neoplasia | |
IL291679A (en) | Gastric cancer treatment using combined treatments containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
IL304820A (en) | Preparations and methods for the treatment of cancer | |
IL253573A0 (en) | Combined therapies for the treatment of cancers | |
HK1209627A1 (zh) | 使用含脂質體伊立替康的組合療法治療胰腺癌的方法 | |
SG11201700079VA (en) | Combination therapy compositions and methods for treating cancers | |
PT3377516T (pt) | Composição para o tratamento do cancro | |
HK1259342A1 (zh) | 用於治療癌症的聯合療法 | |
IL256523A (en) | Compositions and methods for treating cancer | |
IL262656A (en) | Nanoliposomal irinotecan for use in the treatment of small cell lung cancer | |
HK1255939A1 (zh) | 用於治療癌症之組合療法 | |
IL255638A (en) | Compositions and methods for treating cancer | |
EP3468564A4 (en) | METHOD FOR DIAGNOSTICING AND TREATING METASTASIVE CANCER | |
IL270820A (en) | Antisense therapies for cancer treatment | |
EP3303289A4 (en) | Compounds and methods for treating cancer | |
PT3265106T (pt) | Novo método para tratamento e prognóstico do cancro | |
ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
ZA201900438B (en) | Combination therapies for treating cancer | |
PT2892560T (pt) | Métodos e produtos para prevenção e/ou tratamento do cancro metastático | |
HK1250958A1 (zh) | 用於治療癌症的組合物和方法 | |
GB201720089D0 (en) | Means and methods for treating cancer | |
GB201609402D0 (en) | Materials and methods for treating cancer |